Thats a good start on your DD, there is lots more
Post# of 1456
Pros
1. they have increasing revenue qty over qty since the last qtr of 2014
2. talari has bought 9 Million+ shares over the last year
3. their subsidiary web sites are very professional looking, 1st time visitors are not dissapointed
Cons
No S1s on the 3 dividend offerings to shareholders
Changing auditors at the last minute delaying the latest numbers is frustrating
No follow up information on, the June 6th 2014 Uruguay JV agreement or the British Columbia Indian news release which was denied by the Indian tribe.
Lets hope the report coming out has substance to it and not just fluff to draw in buyers.
Other disapointing news has been the spate of court rulings running against MJ. You can bet big pharma is behind a lot of that, they don't want alternative treatments or cures cutting into the bottom line.